Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a Beta-3 adrenergic agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adult patients, improving bladder storage capacity and quality of life.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality controls.

Mirabegron Zentiva is indicated for conditions involving detrusor overactivity within the overactive bladder disease spectrum.

- Overactive bladder: reduces urinary urgency, frequency and episodes of urge incontinence. - Urinary urgency: provides relief by increasing bladder capacity and decreasing sudden urge sensations. - Urinary frequency: helps normalize voiding patterns and improves daily quality of life.

Adverse reactions reported with Mirabegron Zentiva are categorized by frequency.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary retention: difficulty initiating or completing voiding.

Serious or Rare Side Effects: - Severe hypertension: marked increase in blood pressure requiring medical intervention. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema: swelling of face, lips or throat. - Acute urinary retention leading to obstruction. - Allergic reactions: rash, pruritus or anaphylaxis. - QT interval prolongation: potential cardiac conduction disturbance.

Before initiating Mirabegron Zentiva, clinicians should consider the following precautions.

- Monitor blood pressure: check baseline and periodic readings. - Assess renal function: dose adjustment may be needed in impairment. - Evaluate hepatic status: use with caution in severe liver disease. - Review concomitant antihypertensives: mirabegron may reduce their efficacy. - Avoid in uncontrolled hypertension: contraindicated in markedly elevated BP. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with other medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Co‑administration with other β3‑adrenergic agonists: risk of additive cardiovascular effects. - Combined use with antihypertensive agents: may diminish blood pressure control.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise mirabegron levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower mirabegron concentrations. - Diuretics: may potentiate hypertension when mirabegron raises blood pressure.